Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced a collaboration with Ciitizen, a Palo Alto based healthcare technology company that helps patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE).
Search
Recent Posts
See AllIt's a nightmare the very sick can find themselves in: Communicating their health history from one doctor to the next to get the critical care they need. It's been an extra burden during this already
As a nation we have fallen short on the promise of the American Dream, that every generation should enjoy a higher quality of life than the generation before it. US adolescents and young adults are in